Deanna Merrill, PharmD, MBA, AAHIVP

Medical Affairs Scientific Director, Research
ViiV Healthcare

Poster(s):

• (1547) Integrating Long-acting Injectable Cabotegravir for PrEP into Standard of Care for Cisgender Women, Transgender Women, Transgender Men, and Men Who Have Sex with Men: Results from the PILLAR & EBONI Studies
  Friday, October 13, 2023

  12:15 PM – 1:30 PM US ET

• (1550) Engaging Black Women on Cabotegravir LA for PrEP by Optimizing Novel Implementation Strategies (EBONI) Study: Provider Perceptions of Appropriateness of Cabotegravir LA for PrEP for Cis-and-Trans Black Women
  Friday, October 13, 2023

  12:15 PM – 1:30 PM US ET

• (1559) Healthcare Staff Perceptions of Feasibility and Acceptability on Implementing Injectable HIV Pre-exposure Prophylaxis into Standard of Care: Baseline Results from the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR)
  Friday, October 13, 2023

  12:15 PM – 1:30 PM US ET

• (1607) Clinical Outcomes at Month 6 after Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in an Observational Real-World Study (BEYOND)
  Friday, October 13, 2023

  12:15 PM – 1:30 PM US ET